Next 10 |
Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in c...
2024-05-13 10:58:13 ET Summary LPTX is developing DKN-01, a drug with potential in multiple types of cancer, including colorectal, esophagogastric, and endometrial cancer. LPTX's DisTinGuish study looks at DKN-01 in gastric cancer and gastroesophageal cancer patients. Part C of th...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
2024-05-08 13:54:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BeiGene (NASDAQ: BGNE ) just reported results for the first quarter of 2024. BeiGene reported earnings per share of -$2.41. This was above the analyst estimate for EPS of ...
2024-05-08 06:16:40 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene, AbbVie patent spat to get trial from USPTO appeals board EU regulators approve BeiGene's tislelizumab for lung cancer Seeking Alpha’s Quant Rating o...
Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fift...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-05-01 16:12:21 ET More on AbbVie, BeiGene AbbVie: The Inevitable Is Happening Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) BeiGene Still Bleeding Red Ink Despite Blockbuster Drug AbbVie stock slides 6% amid concer...
2024-04-26 11:33:56 ET Summary Shares of AstraZeneca reached new all-time highs this week despite difficult market conditions in the last two months. The revenue and EPS beats were driven by the strong performance of all key growth products. Recent pipeline wins from Imfinzi, ...
Newly released report details Company’s achievements and plans for sustainable growth BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, ...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in c...
Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fift...